NeOnc Technologies Holdings announced its Q1 2026 financial results and operational updates, highlighting progress in its CNS cancer drug programs. The company completed Phase 1 for NEO212, set the Phase 2 dose, and plans a key FDA meeting to discuss pivotal Phase 2 trials and accelerated approval pathways. Its Phase 2a trial for NEO100 is fully enrolled with interim data expected in August 2026. NeOnc also strengthened its finances with a $10 million PIPE investment and appointed a new Chief Accounting Officer, positioning itself for significant clinical and strategic milestones ahead.
Shirofune has introduced Walmart Connect, an integration that allows advertisers and agencies to manage Walmart retail media campaigns alongside other digital channels within a single platform. This automation reduces manual bid adjustments and repor...
Purecore Metals Inc. has signed a non-binding letter of intent with Skyharbour Resources to acquire an option to earn up to 100% interest in the Yurchison uranium property in Saskatchewan's Athabasca Basin. The property covers over 35,000 hectares an...
Point completed a $508.6 million rated asset-backed securitization of its Home Equity Investment (HEI) assets, marking the largest transaction ever in the HEI asset class. The deal attracted over 30 institutional investors and priced at significantly...
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
Industrial Development Funding (IDF) and Oaktree have committed $1.7 billion to support Bloom Energy's fuel cell technology for building AI cloud infrastructure for Nebius. This project will provide dedicated behind-the-meter power to meet the high c...
